Chemotherapy in the afternoon dramatically improves treatment outcomes in female lymphoma patients: Study

Chemotherapy in the afternoon dramatically improves treatment outcomes in female lymphoma patients
The daily fluctuation of proliferative activity of bone marrow is larger in females than in males, and it becomes higher in the morning (left). Thus, chemotherapy in the morning strongly inhibits proliferative activity in female lymphoma patients, resulting in a higher incidence of adverse events such as neutropenia and infections. This forces the clinicians to reduce the dose intensity (center). Consequently, female patients undergoing the morning treatment show a lower survival probability than those undergoing the afternoon treatment (right). Specifically, only ~13% of female patients treated in the afternoon had a worse outcome and ~2% of them died while ~37% of female patients treated in the morning had a worse outcome and ~25% of them died. Male patients did not show any difference in treatment outcomes depending on the chemotherapy delivery time. Credit: Institute for Basic Science

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword. While the drugs are highly effective at killing cancer cells, they are also notorious for killing healthy cells in the body. As such, minimizing the drug's damage to the patient's body is necessary to improve the prognosis of chemotherapy.

Recently, "chronochemotherapy" has been gaining interest in the . As the name suggests, the aim is to time the delivery of the drug to when the body is least vulnerable to the harmful effects of the drug, while the are at their most vulnerable.

Chronochemotherapy exploits the fact that human physiological processes, including and differentiation, are regulated by an endogenous timer called the circadian clock. However, it is not yet widely exploited in real-world because as of now, there is no systematic method to find the optimal chemotherapy delivery time.

This problem was tackled by an interdisciplinary team of researchers from South Korea. They were led by the principal investigators Kim Jae Kyoung (a mathematician at Biomedical Mathematics Group, Institute for Basic Science) and Koh Youngil (an oncologist at Seoul National University Hospital). The researchers studied a group of patients suffering from Diffuse large B-cell lymphoma (DLBCL).

Lymphoma is a type of blood cancer caused by the malignant transformation of lymphoid tissue cells. Lymphoma is divided into Hodgkin's lymphoma and non-Hodgkin's lymphoma (malignant lymphoma), and diffuse large B-cell lymphoma accounts for about 30% to 40% of non-Hodgkin's lymphoma.

The research team noticed that DLBCL patients at Seoul National University Hospital received chemotherapy at two different schedules, with some patients receiving morning treatment (8:30 a.m.), while others taking the drugs in the afternoon (2:30 p.m.). All patients received the same (R-CHOP), which is a combination of targeted therapy and chemotherapy, 4 to 6 times in the morning or afternoon at intervals of about 3 weeks.

They analyzed 210 patients to investigate whether there is any difference between morning and afternoon treatment. It was found that female patients who received afternoon treatment had 12.5 times reduced mortality rate (25% to 2%), while the cancer recurrence after 60 months was decreased by 2.8 times (37% to 13%). In addition, chemotherapy side effects such as neutropenia were more common in female patients who received morning treatment.

Surprisingly, there was no difference in treatment efficiency depending on the treatment schedule in the case of male patients.

To understand the cause of gender differences, the research team analyzed ~14,000 from the Seoul National University Hospital Health Examination Center. It was found that in females, white blood cell counts tend to decrease in the morning and increase in the afternoon. This indicates that the bone marrow proliferation rate is higher in the morning than in the afternoon because there is a ~12hr delay between the bone marrow proliferation and blood cell production.

This means that if a female patient receives chemotherapy in the morning when bone marrow is actively producing blood cells, the possibility of adverse side effects becomes greater. These results are consistent with the findings from recent randomized clinical trials that showed female colorectal cancer patients treated with irinotecan in the morning suffered from higher drug toxicities.

One confounding variable was the drug dose. Since the morning female patients suffered from greater adverse side effects, oftentimes the dose had to be reduced in these patients. On average, the drug dose was reduced by ~10% compared to the dose intensity given to female patients receiving the afternoon treatment.

Unlike , it was found that male patients did not show a significant difference in white blood cell count and bone marrow cell proliferation activity throughout the day, which is the reason why the timing of the treatment had no impact.

Professor Koh Young-il said, "We plan to verify the conclusions of this study again with a large-scale follow-up study that completely controls confounding variables, and to confirm whether chemotherapy has similar effects in other cancers."

Kim Jae Kyung said, "Because the time of the internal circadian clock can vary greatly depending on the individual's sleep-wake patterns, we are currently developing a technology to estimate the time of the from the patient's sleep pattern. We hope that it can be used to develop an individualized anti-cancer chronotherapy."

The findings are published in the journal JCI Insight.

More information: Dae Wook Kim et al, Chemotherapy delivery time affects treatment outcomes of female patients with diffuse large B cell lymphoma, JCI Insight (2022). DOI: 10.1172/jci.insight.164767

Journal information: JCI Insight

Citation: Chemotherapy in the afternoon dramatically improves treatment outcomes in female lymphoma patients: Study (2023, January 24) retrieved 5 February 2023 from https://medicalxpress.com/news/2023-01-chemotherapy-afternoon-treatment-outcomes-female.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

What is CAR-T cell therapy?

51 shares

Feedback to editors